Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

Publisher： Karger

E-ISSN： 1423-0232|81|3-4|143-150

ISSN： 0030-2414

Source： Oncology, Vol.81, Iss.3-4, 2011-10, pp. : 143-150

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-11 ,pp. : 534-541

Karger

Access to resources Recommend Favorite

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

By  

Oncology, Vol. 80, Iss. 3-4, 2011-06 ,pp. : 175-180

Karger

Access to resources Recommend Favorite

Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials

By Li Weibing   Wang Hongbiao   Li Xuyuan  

Current Medical Research and Opinion, Vol. 29, Iss. 11, 2013-11 ,pp. : 1443-1452

Informa Healthcare

Access to resources Recommend Favorite

Clinically Meaningful Responses to Sequential Gemcitabine-Based Chemotherapy Regimens in a Patient with Metastatic Pancreatic Cancer

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-01 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 237-242

Karger

Access to resources Recommend Favorite